|
Global Exosome Development and Manufacturing Services Market Report 2022-2035 with Executive Insights from EVerZom, Clara Biotech, & RoosterBio
Friday, March 25, 2022
DUBLIN, March 22, 2022 /PRNewswire/ -- The "Exosome Development and Manufacturing Services Market, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The "Exosome Development and Manufacturing Services Market" report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of exosome service providers over the next decade. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this field.
Exosomes are extracellular vesicles that play an important role in cell-to-cell communication and act as carriers of circulating nucleic acids, lipids and proteins in body. Over time, various research studies have demonstrated the potential of exosomes in disease diagnosis and drug delivery applications, owing to their ability to act as biomarkers for various diseases and transport important functional elements. Given the various benefits, exosomes have gained significant interest in the biopharmaceutical industry, likely to result in their increased demand.
However, the development and manufacturing of exosomes is associated with several challenges, including lack of standardized isolation and purification methods, limited drug loading ability, and inadequate clinical grade production and GMP compliant industrial scale-up. Therefore, outsourcing of exosome development and manufacturing is seen as a preferable option by companies focused on development of exosome based diagnostics and therapeutics.
Presently, several companies offer services for exosome development and manufacturing. The primary benefit of engaging service providers is to overcome various challenges related to exosome development, such as heterogeneity of exosomes, optimization of exosome isolation, purification and characterization methods and lack of specific biomarkers.
Further, in order to leverage the full potential of exosomes, advanced exosome technologies are being developed to fully substructure their therapeutic applications. In addition, extensive research is being conducted to develop methods for extraction of exosomes with high level of purity and sensitivity.
The growth in research over the last few years is evident from the published scientific literature and the clinical trial activity in this domain. The market has also witnessed substantial partnership activity, including several technology licensing deals. Moreover, the service providers are actively upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these extracellular vesicles.
Driven by the ongoing research activity, technological advancements and efforts of the players offering exosome development and manufacturing services, the market is poised to witness healthy growth over the next decade.
One of the key objectives of the report was to evaluate the existing market size, primary growth factors and opportunity within the exosome development and manufacturing services market in the mid to long term.
In addition to other elements, the report includes:
-- A detailed review of 6,451 peer-reviewed, scientific articles related to
research on exosomes on the basis of several relevant parameters, such
as year of publication, type of service(s) offered, emerging focus
areas. The chapter also highlights the top journals (in terms of number
of articles published and impact factor).
-- A detailed analysis of the global events attended by the participants,
based on several relevant parameters, such as year of event, type of
event platform, location of event, emerging focus areas, active
organizers (in terms of number of events), active industry and
non-industry participants, designation of participants, affiliated
department of participant, active speakers (in terms of number of
events). The chapter also highlights the geographical mapping of
upcoming events.
-- An overview of the landscape of exosome-based technologies, featuring
analyses of various technology providers, based on several relevant
parameters, such as year of establishment, company size and location of
headquarters.
-- An insightful analysis of the patents filed / granted for exosome
technologies, during the period between 2016 and 2021 (till November),
taking into consideration several relevant parameters, such as type of
patent, publication year, application year, geographical location,
Cooperative Patent Classification (CPC) symbols, emerging focus areas,
leading industry and non-industry players (on the basis of number of
patents) and individual patent assignees (in terms of size of
intellectual property portfolio), patent benchmarking, patent
characteristics and age of patents. The chapter also includes an
insightful valuation analysis.
-- A detailed analysis of completed and ongoing clinical trials of
exosomes, based on different parameters, such as trial status, trial
registration year, trial registration year and enrolled patient
population, trial recruitment status, trial phase and number of patients
enrolled, study design, type pf sponsor / collaborator, leading players
(on basis of number of registered trials),emerging focus areas and
location of the trials (on basis of number of registered trials and
enrolled patient population).
Key Questions Answered
-- Who are the leading players offering exosome related services?
-- Which are the various technology platforms available in the market for
the development of exosomes?
-- What is the relative competitiveness of different exosome service
providers?
-- What kind of partnership models are commonly adopted by industry and
non-industry stakeholders?
-- What is the focus area of the ongoing research activities related to
exosomes?
-- How has the intellectual property landscape of exosomes evolved over the
years?
-- What are the key agenda items being discussed in various global events /
conferences related to exosomes?
-- Which companies are actively involved in conducting clinical trials for
exosomes?
-- How is the current and future market opportunity related to exosomes,
likely to be distributed across key market segments?
The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
-- Jonathan Carson (Strategic Marketing Manager, EVerZom)
-- Navdeep Singh (Product Manager and Technical Lead, Clara Biotech)
-- Nicolas Rousseau (Chief Compliance Officer and Co-founder, RoosterBio)
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Extracellular Vesicles
3.2.1. Apoptotic bodies: An Overview
3.2.2. Micro vesicles: An Overview
3.2.3. Exosomes: An Overview
3.3. Composition of Exosomes
3.4. Exosome Biogenesis
3.5 Exosome Development: An Overview
3.6. Manufacturing of Exosomes
3.7. Outsourcing of Exosomes related Services
3.8. Therapeutic Applications of Exosomes
3.8.1. Modification of Immune System
3.8.2. Exosomes as Targeted Drug Delivery Vehicles
3.8.3. Engineered Exosomes
3.9. Challenges Associated with the Development and Manufacturing of Exosomes
3.9.1. Lack of Standardized Isolation and Purification Methods
3.9.2. Limited Drug Loading Ability
3.9.3. Inadequate Clinical Grade Production
3.10. Future Perspectives
4. EXOSOME SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Exosome Service Providers: Developer Landscape
4.3. Analysis by Type of Service(s) Offered
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Scope and Methodology
5.4. Company Competitiveness Analysis: Exosome Service Providers in North America
5.5. Company Competitiveness Analysis: Exosome Service Providers in Europe
5.6. Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World
6. COMPANY PROFILES: EXOSOME SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Creative Bioarray
6.2.2 Creative Biolabs
6.2.3. Creative Biostructure
6.3. Key Players based in Europe
6.3.1. Amsbio
6.3.2. Cambridge Bioscience
6.3.3. Lonza
6.3.4. Qiagen
6.4. Key Players based in Asia-Pacific
6.4.1. Exopharm
6.4.2. Sumika Chemical Analysis Service
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Exosome Service Providers: List of Partnerships and Collaborations
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
10. EXOSOME BASED TECHNOLOGIES: MARKET OVERVIEW
10.1. Chapter Overview
10.2. Exosome Technologies: An Overview
10.3. List of Exosome Technology Providers
10.4 Exosome Technologies: Information of Technology Related Services and Therapeutic Applications
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Exosomes Technologies: Patent Analysis
11.4. Exosome Technologies: Patent Benchmarking Analysis
11.5 Analysis of Patents by Age
11.6. Patent Valuation Analysis
11.7. Leading Patents by Number of Citations
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Analysis by Trial Status
12.4. Analysis by Trial Registration Year
12.5. Analysis by Trial Registration Year and Enrolled Patient Population
12.6. Analysis by Trial Recruitment Status
12.7. Analysis by Trial Phase and Number of Patients Enrolled
12.8. Analysis by Study Design
12.9. Analysis by Type of Sponsor / Collaborator
12.10. Leading Players: Analysis by Number of Registered Trials
12.11. Word Cloud Analysis: Emerging Focus Areas
12.12. Geographical Analysis by Number of Registered Trails
12.13. Geographical Analysis by Enrolled Patient Population
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Exosome Development and Manufacturing Services: Technology Licensing Model
13.4. Global Exosome Development and Manufacturing Services Market, 2022-2035
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. EVerZom
15.3. Clara Biotech
15.4. RoosterBio
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/k33tns
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-exosome-development-and-manufacturing-services-market-report-2022-2035-with-executive-insights-from-everzom-clara-biotech--roosterbio-301507894.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
|
|
